News & Updates

The Washington Post: Gilead delayed safer HIV drug to extend monopoly profits, advocates allege

“Gilead has not only intentionally delayed clinical development of a drug to artificially manipulate its eligibility for a patent-term extension, but it has done so despite the apparent harm to patients,’’ said Christopher Morten, who is supervising attorney at New York University’s Technology Policy and Law Clinic, who filed the petition on behalf of PrEP4All.